Pancreatic ductal adenocarcinoma (PDAC) is characterized by very poor
prognosis. It is caused by asymptomatic course of the disease at early
stage. Symptomatic PDAC means usually advanced stage of the disease,
making radical treatment impossible. Finding of biological PDAC marker
could improve PDAC treatment through early diagnosis. In our study, we
investigated two adipokines: omentin and chemerin concentration in PDAC,
chronic pancreatitis (CP) and healthy individuals. We examined 27 PDAC
patients, 10 CP patients and 36 controls. To determine concentration of
adipokines we used ELISA immunoenzymatic assay. Level of both adipokines
was increased when comparing control group to PDAC patients.
Additionally, chemerin concentration in CP group was elevated comparing
to control. To evaluate both adipokines as potential PDAC biomarkers we
performed ROC analysis. Chemerin (AUC = 0.913) displayed better
discriminant ability than omentin-1 (AUC = 0.73). Some authors believe
that chemerin may promote tumour growth by stimulating angiogenesis and
is supposed to be a factor recruiting mesenchymal stroma cells (MSC) in
tumour regions. Omentin-1 can inhibit tumourigenesis by TP53
stimulation. On the other hand, according to some studies, omentin-1 may
promote cancer proliferation via Akt signalling pathway. Results from
our study showed signifi cantly elevated level of chemerin and omentin-1
in PDAC patients. Th erefore, w e believe that both investigated
adipokines may provide promising and novel pharmacological insights for
oncological diagnosis in the near future.